Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know
Patients with underlying health conditions such as lung cancer are at greater risk for infection or complications from COVID-19. Because of this increased risk, it is important that these patients are carefully managed, with telemedicine replacing in-person visits where possible. However, monitoring patients via telemedicine requires special attention, particularly because symptoms of COVID-19 infection are similar to common adverse events associated with lung cancer treatment.
This activity, “Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know” will provide clinicians with the most up-to-date guidance on managing lung cancer during the current pandemic, including information on the pathophysiology of Sars-Cov-2, the risk of infection in patients with lung cancer, and strategies to manage patient care and counsel through telemedicine.
The intended audience for this educational initiative is clinicians responsible for the daily management of patients with lung cancers.
At the conclusion of this activity, participants should be able to:
• Discuss the most current understanding of the pathophysiology of COVID-19
• Recognize and evaluate factors that increase risk of COVID-19 among patients with lung cancer
• Integrate consensus recommendations for the safe and effective management of patients with lung cancer during the COVID-19 pandemic
• Provide counsel to patients with lung cancer regarding concerns or fears related to COVID-19
This program is supported by an educational grant from Daiichi Sankyo, Inc
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.